Biomarker rediscovery in diagnostics

Expert Opinion on Medical Diagnostics

Volumn 2, Issue 12, 2008, Pages 1391-1400

  Kiernan, Urban A ^a  

^a Intrinsic Bioprobes Incorporated   (United States)

Author keywords

Biomarker discovery; Immunoassay; Mass spectrometry; Post translational modifications; Proteomics

Indexed keywords

AMYLOID A PROTEIN; APOLIPOPROTEIN A1; BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; LEUCINE; PREALBUMIN; RETINOL BINDING PROTEIN 4;

BINDING AFFINITY; CLINICAL RESEARCH; DIAGNOSTIC TEST; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE SEQUENCE; GENETIC HETEROGENEITY; HEALTH SURVEY; HUMAN; IMMUNOASSAY; ION CYCLOTRON RESONANCE MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN MODIFICATION; PROTEIN PROCESSING; PROTEIN TARGETING; PROTEIN VARIANT; PROTEOMICS; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; REVIEW; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY; TWO DIMENSIONAL GEL ELECTROPHORESIS; VALIDITY;

EID: 77953380816     PISSN: 17530059     EISSN: 17530067     Source Type: Journal    
DOI: 10.1517/17530050802566488     Document Type: Review

References (87)

1. National Institutes of Health. Available from: http://www.nih.gov/ index.html [Last accessed on August 2008]
2. National Cancer Institute. Available from: www.cancer.gov [Last accessed on August 2008]
3. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002;1(11):845-67
4. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 2006;24(8):971-83
5. Anderson NL. The roles of multiple proteomic platforms in a pipeline for new diagnostics. Mol Cell Proteomics 2005;4(10):1441-4
6. Peter J, Unverzagt C, Krogh TN, et al. Identification of precursor forms of free prostate-specific antigen in serum of prostate cancer patients by immunosorption and mass spectrometry. Cancer Res 2001;61(3):957-62
7. Mikolajczyk SD, Marker KM, Millar LS, et al. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res 2001;61(118):6958-63
8. Foster DB, Noguchi T, VanBuren P, et al. C-terminal truncation of cardiac troponin I causes divergent effects on ATPase and force: implications for the pathophysiology of myocardial stunning. Circ Res 2003;93(10):917-24
9. Yu ZB, Zhang LF, Jin JP. A proteolytic NH2-terminal truncation of cardiac troponin I that is up-regulated in simulated microgravity. J Biol Chem 2001;276(19):15753-60
10. Wilkins MR, Sanchez JC, Gooley AA, et al. Progress with proteome projects: why all proteins expressed by a genome should be identified and how to do it. Biotechnol Genet Eng Rev 1996;13:19-50
11. O'Farrell PH. High resolution two-dimensional electrophoresis of proteins. J Biol Chem 1975;250(10):4007-21
12. Gygi SP, Corthals GL, Zhang Y, et al. Evaluation of two-dimensional gel electrophoresis-based proteome analysis technology. Proc Natl Acad Sci USA 2000;97(17):9390-5
13. Page JS, Masselon CD, Smith RD. FTICR mass spectrometry for qualitative and quantitative bioanalyses. Curr Opin Biotechnol 2004;15(1):3-11
14. Washburn MP, Wolters D, Yates JR 3rd. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat Biotechnol 2001;19(3):242-7
15. HUPO 3rd World Congress on Proteomics, Beijing, China, October 25th, 2004, Plasma Proteome Session, AvaiIable from: hrtp://www.hupo.org/ research/files/PPP_January_2003_Omenn.pdf [Viewed August 2008]
16. Anderson NL, Polanski M, Pieper R, et al. The human plasma proteome: a nonredundant list developed by combination of four separate sources. Mol Cell Proteomics 2004;3(4):311-26
17. Liotta LA, Kohn EC, Petricoin EF. Clinical proteomics: personalized molecular medicine. Jama 2001;286(18):2211-4
18. Petricoin EF, Zoon KC, Kohn EC, et al. Clinical proteomics: translating benchside promise into bedside reality. Nat Rev Drug Discov 2002;1(9):683-95
19. Krieg RC, Paweletz CP, Liocra LA, Petricoin EF, 3rd. Clinical proteomics for cancer biomarker discovery and therapeutic targeting. Technol Cancer Res Treat 2002;1(4):263-72
20. Issaq HJ, Conrads TP, Prieto DA, et al. SELDI-TOF MS for diagnostic proteomics. Anal Chem 2003;75(7)A148-55
21. Tang N, Tornatore P, Weinberger SR. Current developments in SELDI affinity technology. Mass Spectrom Rev 2004;23(1):34-44
22. Kuwata H, Yip TT, Yip CL, et al. Bactericidal domain of lactoferrin: detection, quantitation, and characterization of lactoferricin in serum by SELDI affinity mass spectrometry. Biochem Biophys Res Commun 1998;245(3):764-73
23. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359(9306):572-7
24. Chen YD, Zheng S, Yu JK, Hu X. Artificial neural networks analysis of surface-enhanced laser desorption/ionization mass spectra of serum protein pattern distinguishes colorectal cancer from healthy population. Clin Cancer Res 2004;10(24):8380-5
25. Ornstein DK, Rayford W, Fusaro, VA, et al. Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml. J Urol 2004;172(4 Pt 1):1302-5
26. Koopmann J, Zhang Z, White N, et al. Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res 2004;10(3):860-8
27. Junket K, Gneist J, Melle C, et al. Identification of protein pattern in kidney cancer using ProteinChip(R) arrays and bioinformatics. Int J Mol Med 2005;15(2):285-90
28. Kang X, Xu Y, Wu X, et al. Proteomic fingerprints for potential application to early diagnosis of severe acute respiratory syndrome. Clin Chem 2005;51(1):56-64
29. Shiwa M, Nishimura Y, Wakatabe R, et al. Rapid discovery and identification of a tissue-specific tumor biomarker from 39 human cancer cell lines using the SELDI ProteinChip platform. Biochem Biophys Res Commun 2003;309(1):18-25
30. Wulfkuhle JD, Liotta LA, Petricoin EF. Proteomic applications for the early detection of cancer. Nat Rev Cancer 2003;3(4):267-75
31. Petricoin E, Wulfkuhle J, Espina V, Liotta LA. Clinical proteomics: revolutionizing disease detection and patient tailoring therapy. J Proteome Res 2004;3(2):209-17
32. Petricoin EF, Fishman DA, Conrads TP, et al. Lessons from Kitty Hawk: from feasibility to routine clinical use for the field of proteomic pattern diagnostics. Proteomics 2004;4(8):2357-60
33. Johann DJ, Jr, Mc Guigan MD, Patel AR, et al. Clinical proteomics and biomarker discovery. Ann NY Acad Sci 2004;1022:295-305
34. Rockhill B. Proteomic patterns in serum and identification of ovarian cancer. Lancet 2002;360(9327):169; author reply 70-1
35. Pearl DC. Proteomic patterns in serum and identification of ovarian cancer. Lancet 2002;360(9327):169-70; author reply 70-1
36. Elwood M, Proteomic patterns in serum and identification of ovarian cancer. Lancet 2002;360(9327):170; author reply-1
37. Sorace JM, Zhan M. A data review and re-assessment of ovarian cancer serum proteomic profiling. BMC Bioinformatics 2003;4(1):24
38. Baggerly KA, Morris JS, Edmonson SR, Coombes KR. Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer. J Natl Cancer Inst 2005;97(4):307-9
39. Diamandis EP. Point: Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? Clin Chem 2003;49(8):1272-5
40. Diamandis EP. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst 2004;96(5):353-6
41. Diamandis EP. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol Cell Proteomics 2004;3(4):367-78
42. Diamandis EP. Proteomic patterns to identify ovarian cancer: 3 years on. Expert Rev Mol Diagn 2004;4(5):575-7
43. Coombes KR, Morris JS, Hu J, et al. Serum proteomics profiling-a young technology begins to mature. Nat Biotechnol 2005;23(3):291-2
44. Ransohoff DF. Lessons from controversy: ovarian cancer screening and serum proteomics. J Natl Cancer Inst 2005;97(4):315-9
45. Zhang Z, Bast RC, Jr., Yu Y, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004;64(16):5882-90
46. Paradis V, Degos F, Dargere D, et al. Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases. Hepatology 2005;41(1):40-7
47. Tolson J, Bogumil R, Brunst E, et al. Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients. Lab Invest 2004;84(7):845-56
48. Cho WC, Yip TT, Yip C, et al. Identification of serum amyloid a protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling. Clin Cancer Res 2004;10(1 Pt 1):43-52
49. Le L, Chi K, Tyldesley S, et al. Identification of Serum Amyloid A as a Biomarker to Distinguish Prostate Cancer Patients with Bone Lesions. Clin Chem 2005;51(4):695-707
50. Howard BA, Wang MZ, Campa MJ, et al. Identification and validation of a potential lung cancer serum biomarker detected by matrix-assisted laser desorption/ionization-time of flight spectra analysis. Proteomics 2003;3(9):1720-4
51. Koomen JM, Shih LN, Coombes KR, et al. Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. Clin Cancer Res 2005;11(3):1110-8
52. Baumann H, Gauldie J. The acute phase response. Immunol Today 1994;15(2):74-80
53. Kushner I. The phenomenon of the acute phase response. Ann NY Acad Sci 1982;389:39-48
54. Nedelkov D, Tubbs KA, Niederkofler EE, et al. High-Throughput Comprehensive Analysis of Human Plasma Proteins: A Step toward Population Proteomics. Anal Chem 2004;76(6):1733-7
55. Nedelkov D, Kiernan UA, Niederkofler EE, et al. Investigating diversity in human plasma proteins. Proc Natl Acad Sci USA 2005;102(31):10852-7
56. Craig WY, Ledue TB, Ritchie RF. Plasma proteins: Clinical utility and interpretation. Scarborough, ME: Foundation for Blood Research, 2001
57. Ritchie RF, editor,. Serum Proteins in Clinical Medicine. Scarborough, ME: Foundation for Blood Research 1999
58. Chakraborty A, Regnier FE. Global internal standard technology for comparative proteomics. J Chromatogr A 2002;949(1-2):173-84
59. Schmidt A, Kellermann J, Lottspeich F. A novel strategy for quantitative proteomics using isotope-coded protein labels. Proteomics 2005;5(1):4-15
60. Gygi SP, Rist B, Gerber SA, et al. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol 1999;17(10):994-9
61. Steel LF, Haab BB, Hanash SM. Methods of comparative proteomic profiling for disease diagnostics. J Chromatogr B Analyt Technol Biomed Life Sci 2005;815(1-2):275-84
62. Villanueva J, Philip J, Entenberg D, et al. Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. Anal Chem 2004;76(6):1560-70
63. Zhang X, Leung SM, Morris CR, Shigenaga MK. Evaluation of a novel, integrated approach using functionalized magnetic beads, bench-top MALDI-TOF-MS with prestructured sample supports, and pattern recognition software for profiling potential biomarkers in human plasma. J Biomol Tech 2004;15(3):167-75
64. Stoeckli M, Chaurand P, Hallahan DE, Caprioli RM. Imaging mass spectrometry: a new technology for the analysis of protein expression in mammalian tissues. Nat Med 2001;7(4):493-6
65. Engvall E, Perlmann P. Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G. Immunochemistry 1971;8(9):871-4
66. Van Weemen BK, Schuurs AH. Immunoassay using antigen-enzyme conjugates. FEBS Lett 1971;15(3):232-6
67. Nelson RW, Krone JR, Bieber AL, Williams P. Mass-Spectrometric Immunoassay. Anal Chem 1995;67(7):1153-8
68. Niederkofler EE, Tubbs KA, Gruber K, et al. Determination of beta-2 microglobulin levels in plasma using a high-throughput mass spectrometric immunoassay system. Anal Chem 2001;73(14):3294-9
69. Kiernan UA, Tubbs KA, Gruber K, et al. High-Throughput Protein Characterization Using Mass Spectrometric Immunoassay. Anal Biochem 2002;301(1):49-56
70. Nedetkov D. Population proteomics: addressing protein diversity in humans. Expert Rev Proteomics 2005;2(3):315-24
71. Tubbs KA, Nedelkov D, Nelson RW. Detection and quantification of beta-2-microglobulin using mass spectrometric immunoassay. Anal Biochem 2001;289(1):26-35
72. Tubbs KA, Kiernan UA, Niederkofler EE, et al. Development of recombinant-based mass spectrometric immunoassay with application to resistin expression profiling. Anal Chem 2006;78(10):3271-6
73. Kiernan UA, Addobbati R, Nedelkov D, Nelson RW. Quantitative multiplexed C-reactive protein mass spectrometric immunoassay. J Proteome Res 2006;5(7):1682-7
74. Kiernan UA, Nedelkov D, Nelson RW. Multiplexed mass spectrometric immunoassay in biomarker research: a novel approach to the determination of a myocardial infarct. J Proteome Res 2006;5(11):2928-34
75. Kiernan UA, Tubbs KA, Nedelkov D, et al. Comparative urine protein phenotyping using mass spectrometric immunoassay. J Proteome Res 2003;2(2):191-7
76. Kiernan UA, Tubbs KA, Nedelkov D, et al. Comparative phenotypic analyses of human plasma and urinary retinol binding protein using mass spectrometric immunoassay. Biochem Biophys Res Commun 2002;297(2):401-5
77. Kiernan UA, Tubbs KA, Nedelkov D, et al. Detection of novel truncated forms of human serum amyloid A protein in human plasma. FEBS Lett 2003;537(1-3):166-70
78. Kiernan UA, Nedelkov D, Tubbs KA, et al. Selected Expression Profiling of Full-Length Proteins and Their Variants in Human Plasma. Clin Proteomics J 2004;1(1):7-16
79. Theberge R, Connors L, Skinner M, et al. Characterization of transthyretin mutants from serum using immunoprecipitation, HPLC/ electrospray ionization and matrix-assisted laser desorpdon/ionization mass spectrometry. Anal Chem 1999;71(2):452-9
80. Lacey JM, Bergen HR, Magera MJ, et al. Rapid determination of transferrin isoforms by immunoaffinity liquid chromatography and electrospray mass spectrometry. Clin Chem 2001;47(3):513-8
81. Sen JW, Bergen HR, 3rd, Heegaard NH. On-line immunoaffinity-liquid chromatography-mass spectrometry for identification of amyloid disease markers in biological fluids. Anal Chem 2003;75(5):1196-202
82. Xiao Z, Adam BL, Cazares LH, et al. Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res 2001;61(16):6029-33
83. Nedelkov D, Phillips DA, Tubbs KA, Nelson RW. Investigation of human protein variants and their frequency in the general population. Mol Cell Proteomics 2007;6(7):1183-7
84. Kiernan UA, Nedelkov D, Tubbs KA, et al. Proteomic characterization of novel serum amyloid P component variants from human plasma and urine. Proteomics 2004;4(6):1825-9
85. Jaconi S, Rose K, Hughes GJ, et al. Characterization of two post-translationally processed forms of human serum retinol-binding protein: altered ratios in chronic renal failure. J Lipid Res 1995;36(6):1247-53
86. Graham TE, Yang Q, Bluher M, et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 2006;354(24):2552-63
87. Baker M. New-wave diagnostics. Nat Biotechnol 2006;24(8):931-8